‘Cult' of tourniquets causing thousands of unnecessary amputations and deaths in Ukraine, say surgeons
Captain Rom A Stevens, a retired senior US medical navy officer who has served in Iraq, Afghanistan, and East Africa, estimates that of the roughly 100,000 amputations performed on Ukrainian soldiers since Russia's full-scale invasion in 2022, as many as 75,000 were caused by improper use of tourniquets.
'I've seen tourniquets that have been left on for days, often for injuries that could have been stopped by other methods. Then [the patient] has to have their limb amputated because the tissue has died,' Captain Stevens told The Telegraph.
Tourniquets are strong bands used to stop catastrophic bleeding by cutting off blood flow, and are standard issue for most modern armies.
But if left on over two hours, they can cause tissue death, meaning the arm or leg which has the tourniquet on is no longer viable and requires amputation.
The device became standard-issue in the 2000s wars in Iraq and Afghanistan, where rapid air evacuation to military surgical teams was possible in under 60 minutes. If the tourniquet was unnecessary it was removed, and no harm was done.
But in Ukraine, where the skies are infested with drones, injured soldiers are evacuated by land, often far exceeding the safe time window for tourniquet use.
This critical delay has caused tens of thousands of amputations, say experts, many of which were unnecessary because the injuries didn't require a tourniquet in the first place.
It has also led to a sharp rise in young Ukrainians needing dialysis, said Captain Stevens who has served as a medical volunteer in hospitals in Zaporizhzhiya, Dnipro, and L'viv since the invasion in 2022.
This is because when a tourniquet is removed after being kept on too long, toxins from dead tissue flood the bloodstream, overwhelming the kidneys.
Captain Stevens helped draft the US military guidelines for tourniquet use and now wishes greater emphasis had been placed on assessing when they were needed to stop bleeding.
He fears that their successful use in wars where rapid evacuation was possible has led to a 'cult-like' dependence on a tool that should be used much more sparingly.
In Ukraine, it has left 'a generation of men traumatised by unnecessary amputations,' he said.
The US Tactical Combat Casualty Care (TCCC) handbook was created for trained military medics operating in war zones in the 1990s and heavily promotes the use of tourniquets in war, describing their use as 'the best method to control life-threatening bleeding'.
Widely adopted by NATO and Western armed forces in the early 2000s, the TCCC standards were quickly integrated into Ukrainian military and civilian medical training following the Russian invasion of Crimea in 2014.
Captain Stevens – though an author of the TCCC – says this was a error.
'If you have a perfect battlefield, then tourniquets work. But if you don't – if you have a situation like Ukraine today – you can end up with a tragedy. And that's what the Ukrainians have,' he said.
'There's now hundreds of thousands of tourniquets that have been distributed to military forces, civilians, fire departments, and police in Ukraine. It's become a cult, and because it saved lives in Iraq and Afghanistan, people think it's a good idea,' he added.
While most Western militaries embed specialist medics in every unit, Ukraine's armed forces – made up largely of conscripts and civilian volunteers – often rely on medics with only a few weeks or even days of training who are often unable to distinguish between injuries that do and don't require tourniquets.
'The Ukrainian infantry and artillery battalions are undermanned. They can't replace their medics when they get injured or killed,' Captain Stevens said.
A 2022 study by a Ukrainian military vascular surgeon, Dr Vladyslav Yatsun, found that only 24.6 per cent of war wounded patients arriving at hospital with tourniquets had injuries that justified their use to stop bleeding.
'In all other cases, the use of pressure bandages was more appropriate,' the study said.
They are also often being applied too high on damaged limbs, said Captain Stevens. 'They are often taught to place on the tourniquets well above the wounds, and the result is a very high amputation, making it difficult to later fit a prosthesis,' he said.
An updated version of the Ukrainian TCCC disseminated to the armed forces in January 2024 specifically reads: 'Place the tourniquet 'high and tight' on the wounded extremity.'
NATO has also raised concerns about tourniquets in Ukraine.
Last year, the agency dispatched a team of medical and military experts to investigate what it described as 'an unacceptable high complication rate from the use of tourniquets [...] resulting in amputations, renal failure and even death.'
The organisation added: 'The current situation with prolonged evacuation times requires a shift in attitude towards tourniquets,' although it has yet to formally publish its recommendations.
Experts stress that tourniquets continue to save many lives and should not be abandoned.
Instead, they say that in places like Ukraine where rapid evacuation is difficult they should only be used in the three circumstances in which they are absolutely necessary.
The first is when a limb has been completely severed. 'In that situation, you need a tourniquet, but you need to put it as low down as possible to try and save as much of the limb as you can,' said Captain Stevens.
The second is when the limb is so damaged that it cannot be saved – a decision that requires judgement and medical experience.The third is when a person has uncontrolled arterial bleeding that cannot be stopped with direct pressure or any other method.
Captain Stevens said tourniquets are often applied by panicked soldiers, who lack the knowledge or confidence to try other methods first.
'When a [Ukrainian] soldier is injured in the field, they're usually taken care of by other soldiers in a panic,' he said. 'They see blood. They put on tourniquets because they have tourniquets. We gave them tourniquets.'
Dr Ostap Zubach, an orthopaedic surgeon who works at a major trauma hospital in L'viv, agrees that while tourniquets can be life-saving, they can also be deadly when used incorrectly.
'As a doctor, I believe that in the right hands, tourniquets are a brilliant thing. But in the wrong hands, they can be very dangerous,' he said.
A particular problem was that many soldiers did not know how to temporarily loosen a tourniquet periodically to extend the time of safe use.
'The strategy of tourniquets [in Ukraine] is just not working, especially when [the soldiers] don't know how to convert them,' said Dr Zubach. 'Many of our soldiers have no experience in the military or medicine.'
Major General Anatoliy Petrovych Kazmirchuk, Commander of the Medical Forces of the Ukrainian Army, introduced tourniquet 'conversion' into the basic military training programme last year following reports of excessive amputations and limb loss at the front.
But both Captain Stevens and Dr Zubach are sceptical on what impact the new training is having.
'The problem is that under fire, people are afraid to take the tourniquets down. They're in a rush to get that patient to a hospital surgeon and don't stop to convert them,' said Captain Stevens.
A growing group of medics both in and outside of Ukraine are now putting pressure on the ministry of defence to move away from the TCCC handbook and develop their own set of medical guidelines for use in the Ukrainian context, factoring in long evacuation times.
'Guidelines are only guidelines. They require common sense to apply, they require professional judgement. In Ukraine, they don't have a system for developing guidelines. Often they just take Western, US, British, NATO guidelines, and translate them, word for word into Ukrainian,' said Captain Stevens.
'But there's a lot of resistance to changing it. The Ukrainians are taking their cue from the Americans, but our protocols were not designed for this situation,' he added.
'If you go back to World War Two and you read what the American theatre surgeons had to say about tourniquets, they said they were dangerous because they were often placed on wounds that did not require them, and then not taken off before it was too late,' he said.
'You didn't have a rapid evacuation there either. You're evacuating by land, over bumpy roads, in the middle of the night under fire, just like what the Ukrainians are doing now.'
Both Dr Zubach and Captain Stevens say more emphasis needs to be put on basic casualty care, like cutting off clothes to examine the wound to see the source of bleeding, use of pressure bandages, and alginates – jelly-like dressings that can absorb heavy bleeding and pack into wounds without the long-term risks associated with a tourniquet.
Both agree that tourniquets should be used only as a last resort, when all else has failed. 'Soldiers and medics need to understand that when a tourniquet is placed on the Ukrainian battlefield, it usually means an amputated limb,' says Stevens.
Protect yourself and your family by learning more about Global Health Security
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
2 hours ago
- Bloomberg
Macquarie to Buy Stake in Portuguese Hospital Group Luz Saude
Macquarie Group Ltd. is set to buy a minority stake in Portuguese hospital operator Luz Saude SA, outbidding rivals CVC Capital Partners Plc and KKR & Co., according to people familiar with the matter. Sydney-based Macquarie agreed to purchase about 40% of Luz Saude from Fidelidade-Companhia de Seguros SA, a Portuguese insurer controlled by Chinese conglomerate Fosun International Ltd, said the people, who asked not to be named because the information is confidential. The deal could be signed in the coming days and would give Luz Saude an enterprise value of more than €1 billion, one of the people said.
Yahoo
2 hours ago
- Yahoo
Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastructure, supportive government policies, heavy R&D investment, and contributions from pharmaceutical giants like Novo Nordisk and Lundbeck. The aging population, rise in chronic diseases, and demand for innovative treatments further fuel growth. However, challenges such as regulatory complexity and sustainability pressures persist. The market encompasses a wide range of therapeutic classes and distribution channels, making Denmark a competitive hub for pharmaceutical R&D and innovation. Danish Pharmaceutical Market Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Denmark Pharmaceutical Market - Drug Development & Forecast 2025-2033" report has been added to Pharmaceutical Market is expected to reach US$ 5.20 billion by 2033 from US$ 3.81 billion in 2024, with a CAGR of 3.52% from 2025 to 2033 Heavy R&D spending, government assistance, well-developed healthcare system, aging population, growth in the incidence of chronic diseases, advances in biotechnology, world demand for exports, and the location of world-class pharmaceutical giants such as Novo Nordisk and Lundbeck are all determinants of Denmark's expanding pharmaceutical market. Investigation, research, production, and promotion of drugs and therapies utilized to cure, prevent, or control disease fall within the pharmaceutical sector. Through the provision of innovative medical treatments and increased life expectancy and quality of life, it plays an important role in world medicine. Scientific breakthroughs, government approvals, and the ongoing demand for effective treatments drive this industry. Both small biotech firms and international corporations are prominent players. Prescription drugs, vaccines, and over-the-counter drugs are all pharmaceuticals. The sector often collaborates with research and clinical institutions to accelerate development and is highly regulated to ensure safety and efficacy of R&D expenditures, a collaborative academic and health environment, and supportive government regulations are the primary impetus for Denmark's pharmaceutical industry. Major contributions are made by leading global companies such as Novo Nordisk and Lundbeck through specialty medicine creation and global exports. Demand within the domestic market is also boosted by an aging population and the spread of chronic diseases such as diabetes. Innovation through personalized therapy and real-world evidence creation are enabled by advanced health data infrastructure in Denmark. Its global competitiveness is enhanced by an open regulatory system and access to EU markets. These combine to offer a robust, future-proof pharmaceutical sector with scope to Drivers for the Denmark Pharmaceutical Market Advanced Health Data InfrastructureOne of the key drivers for Denmark's pharmaceutical market's growth is its advanced heath data infrastructure. With biobanks, illness registries, and population-level electronic health records, the country boasts one of the most advanced and unified systems of healthcare data in the world. Since every Danish citizen is assigned a personal identification number, medical records can be exactly correlated between clinics, hospitals, and pharmacies. The approach opens up real-world data to academics and pharma companies to facilitate post-marketing surveillance, drug development, and clinical trials. Such access reduces the cost and time-to-market of research as well as speeds up pharmacovigilance and personalized treatment innovation. It also enhances the quality and efficiency of clinical trials by enabling long-term follow-up and targeted patient recruitment. In addition, Denmark is a safe destination for international collaboration due to the stringent data protection legislation that ensures patient confidentiality. This technological advantage enhances Denmark's competitiveness in the life sciences world and makes it a leading site for pharmaceutical R& Government PoliciesDenmark's pharma industry is growing largely due to the favorable government policies of the country. Denmark has established a comprehensive Life Sciences Growth Plan incorporating 36 initiatives across six key areas such as clinical trials, R&D, and regulatory environments. This strategic plan aims to further consolidate Denmark's reputation as a leading life sciences nation by fostering innovation and streamlining establishment of a "one-stop-shop" for drug companies that simplifies and quickens the regulatory approval process is an essential component of this program. By reducing administrative barriers, this program makes it easier for businesses to set up and expand production sites in Denmark. In addition, Denmark's climate agreement with the pharmaceutical industry illustrates its commitment to environmental responsibility. Consistent with international environmental aims, our partnership works to support green innovation and reduce CO2 emissions. Overall, taken as a package, all these beneficial government programs offer a good environment for pharmaceutical companies to expand, innovate, and become globally competitive for Denmark's pharmaceutical R&D InvestmentHigh investment in research and development (R&D) is one of the factors propelling the growth of the pharmaceutical market in Denmark. With a significant proportion being allocated to life sciences and pharmaceuticals, the country has some of the highest R&D expenditures per GDP of any nation globally. Both the public funding of the Danish government and substantial contributions from the private sector - particularly from major players such as Novo Nordisk and Lundbeck - funding this hospitals, and enterprise are in close collaboration to facilitate Denmark's R&D environment that encourages innovation in biotechnology, personalized medicine, and drug development. Tax reductions, subsidies, and strategic initiatives such as the Life Sciences Growth Plan are some of the government measures that actively encourage R&D. Contemporary research infrastructure and highly skilled staff are also available, which adds to Denmark's competitive edge. This robust R&D climate accelerates the development of novel treatments, attracts foreign partnerships, and makes Denmark a world leader in clinical excellence and pharmaceutical in the Denmark Pharmaceutical Market Regulatory Complexity and EU ComplianceEU compliance and regulatory complexity provide major obstacles for Denmark's pharmaceutical industry. Businesses have to deal with two sets of regulations: strict European Union guidelines and Danish state laws. This results in a complicated and frequently drawn-out approval process for new medications and clinical studies, which can raise expenses and postpone market entry. Startups and small and medium-sized businesses (SMEs) frequently find it difficult to satisfy these standards due to the resource requirements and administrative load. Furthermore, ongoing adaptation is necessary due to the EU's periodic revisions and harmonization initiatives. For Danish pharmaceutical businesses, sustaining innovation speed while balancing compliance is still a major and Green TransitionFor Denmark's pharmaceutical industry, sustainability and the green transition pose increasing obstacles. There is growing pressure on the business to lessen its environmental impact, which includes controlling water use in manufacturing processes, cutting carbon emissions, and limiting waste. Significant investments in cleaner technologies and process innovations are necessary to meet Denmark's aggressive climate targets and EU environmental requirements. Pharmaceutical businesses also need to strike a balance between sustainability measures and preserving cost-effectiveness and production efficiency. Changes in sourcing procedures and supply networks are also necessary for this shift. The Danish pharmaceutical industry must overcome the difficult task of successfully incorporating green practices while maintaining its competitiveness in order to keep up with worldwide sustainability trends. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, SWOT Analysis, Sales Analysis Novo Nordisk A/S H. Lundbeck A/S Leo Pharma A/S Orifarm Group A/S ALK-Abell A/S Xellia ApS Takeda Pharma A/S Sandoz A/S Ferring Pharmaceuticals A/S FUJIFILM Diosynth Biotechnologies Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $3.81 Billion Forecasted Market Value (USD) by 2033 $5.2 Billion Compound Annual Growth Rate 3.5% Regions Covered Denmark Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Denmark Pharmaceutical Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Therapeutic Class6.2 By Drug Type6.3 By Prescription Type6.4 By Distribution Channel7. Therapeutic Class7.1 Cancer7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Infectious Diseases7.3 Cardiovascular Diseases7.4 Diabetes7.5 Respiratory Diseases7.6 Central Nervous System Disorders7.7 Autoimmune Diseases7.8 Others8. Drug Type8.1 Branded8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Generic9. Prescription Type9.1 OTC Drugs9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Prescription Drugs10. Distribution Channel10.1 Hospital Pharmacy10.1.1 Market Analysis10.1.2 Market Size & Forecast10.2 Retail Pharmacy10.3 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Novo Nordisk A/S14.2 H. Lundbeck A/S14.3 Leo Pharma A/S14.4 Orifarm Group A/S14.5 ALK-Abell A/S14.6 Xellia ApS14.7 Takeda Pharma A/S14.8 Sandoz A/S14.9 Ferring Pharmaceuticals A/S14.10 FUJIFILM Diosynth Biotechnologies15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Danish Pharmaceutical Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Washington Post
3 hours ago
- Washington Post
A Danish zoo is seeking unwanted pets — to feed to its predators
A zoo in Denmark has put out a call for people to donate unwanted pets and animals — including chickens, rabbits and guinea pigs — so they can be turned into feed for its predators. Aalborg Zoo wrote on social media last week that healthy animals it receives will be 'gently euthanized' by trained staff and then used as food for the predators, adding that this would help the zoo replicate its animals' natural food chain. 'That way, nothing goes to waste — and we ensure natural behavior, nutrition and well-being of our predators,' the zoo said, adding that some of its animals needed to eat 'whole' prey. The zoo also accepts donations of certain horses, which are also euthanized and then used as food. Online, critics balked at the idea of pets being fed to zoo animals, calling it a 'cheap publicity stunt,' 'disrespectful' and 'sick,' and a policy they say could encourage pet neglect. However, others said it was a good option for people whose pets are nearing the end of their lives and a way to make sure their deaths serve a purpose. Experts say donation can be a more cost-effective and natural way of feeding zoo animals who might otherwise be fed meat from commercial sources that can come from animals raised in poor conditions. 'If you agree to the general principle that you have carnivorous animals in a zoo, you somehow succumb to the necessity that you have to feed them animal material,' Marcus Clauss, co-director of the Clinic for Zoo Animals, Exotic Pets and Wildlife at the University of Zurich, said in an interview. 'If you do this in a way that is not primarily directed at economics, but at animal welfare, you will strive to get animals that had high welfare, ideally.' Aalborg Zoo did not immediately respond to a request for comment Tuesday. In a statement shared with the outlet Popular Science, spokeswoman Pia Nielsen said the practice of feeding carnivorous animals with smaller livestock has been used at Aalborg Zoo for many years and is common in Denmark. 'When keeping carnivores, it is necessary to provide them with meat, preferably with fur, bones, etc., to give them as natural a diet as possible. Therefore, it makes sense to allow animals that need to be euthanized for various reasons to be of use in this way,' Nielsen told Popular Science. 'In Denmark, this practice is common, and many of our guests and partners appreciate the opportunity to contribute.' Zoos in other countries also accept donations of livestock, or deceased animals, to feed their predators. The Wild Spirit Wolf Sanctuary in New Mexico, for example, states on its website that it accepts donations of 'livestock that has passed away or needs to be humanely euthanized' to feed its wolves and recommends donation over 'having to dispose of the deceased in a landfill, or go through the costly process of cremation.' The Alaska Zoo in Anchorage recently put out a call for frozen meat and fish donations for its animals. Clauss said that when horses are slaughtered, 'you have a huge amount of animal — meat, bones, etc. — that goes to waste in our system because it's not used by humans.' He said he supports zoos offering people the option of donating their horses if the alternative is that zoos purchase horsemeat to feed their carnivores. 'Why not get it that way directly?' Clauss acknowledged concerns that encouraging people to donate animals might mean fewer unwanted pets are placed in shelters. But he said pet shelters in many countries, including the United States, are overcrowded and can't always ensure optimal conditions for the pets in their care, so that option might not guarantee a higher welfare for the unwanted animals. And he said that forcing someone who doesn't want or can't afford their pet to keep them may also not be good for the animal. 'People who want to get rid of their animals will find a way of doing that,' he said. In response to the call for donations by the Aalborg Zoo, several Facebook users wrote that they took their horses to be donated there and praised the zoo's handling of their animals, while others wrote that they were planning to donate their horses in the future. It was not immediately clear how the donated animals would be euthanized. On Facebook, the zoo said trained professionals worked to make the deaths as quick and painless as possible.